Closing

Do GLP-1 receptor agonists improve kidney outcomes versus placebo?

Mostly studied in obesity & overweight.

Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →

Where the evidence stands

A coin flip. So far, the results disagree.

NoUnsureYes
Belief
0.50 (range 0.00–0.55)
Trials for
2
Trials against
1
Inconclusive
5

Already under way

The evidence so far

Registered trials
119
With posted results
41
Published papers
6

Of 32 decided analyses: 5 favor glp-1 receptor agonists, 26 find no difference, 1 favor the comparator.

Papers

Trials

See every trial in the evidence map →